Vysioneer reports prospective AI assessment in an oncology trial

On October 20, 2026, Vysioneer announced that its VTrial AI platform was prospectively deployed in a pharmaceutical-sponsored oncology clinical trial to support treatment-efficacy assessment.

The ESMO 2026 abstract describes AI-assisted RECIST 1.1 assessment in a phase 1 study of fetrastobart vedotin in patients with non-small cell lung cancer. The company reports that an independent AI-assisted central read produced confirmed objective response and disease-control rates consistent with local investigator assessments.

Vysioneer says the work demonstrates the feasibility of using AI-assisted assessment in an active trial, rather than only in retrospective analyses. The company characterizes it as the first reported prospective use of AI-assisted RECIST 1.1 as an efficacy endpoint in a pharma-sponsored oncology trial.

The poster presentation is listed for October 25, 2026, at ESMO. The announcement describes potential value for more consistent efficacy evidence and clinical-development decisions; it does not establish that the approach improves patient outcomes or speeds drug development.